Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E MINAR

Showing results (51-60 of 194) with videos related to

Pageof 20
Sort By:
VASA. Zeitschrift Fur Gefasskrankheiten|January 1, 1984
[Thrombolysis using urokinase in acute phlebothrombosis]E Minar, H Ehringer, L Marosi, et al.
Thrombosis and Haemostasis|October 22, 1990
D-dimer in local thrombolytic therapy with low doses of recombinant human tissue-type plasminogen activator (rt-PA) in patients with peripheral arterial occlusive diseaseR Koppensteiner, W Speiser, E Minar, et al.
VASA. Supplementum|January 1, 1990
[Percutaneous transluminal angioplasty of subclavian stenoses]A Ahmadi, E Minar, R Koppensteiner, et al.
Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association|January 1, 1983
Pyridoxine therapy in patients with renal calcium oxalate calculiP Balcke, P Schmidt, J Zazgornik, et al.
Zeitschrift Fur Kardiologie|November 1, 1986
[Complete AV block in a heart catheter study using a Swan-Ganz catheter]G Mostbeck, A Gassner, G Sommer, et al.
Annals of Hematology|October 11, 2003
Influence of systemic inflammation on efficiency of antiplatelet therapy in PAOD patientsS Ziegler, E Alt, M Brunner, et al.
Thrombosis Research|September 25, 2001
Coadministration of low-dose urokinase and abciximab in thrombolysis for lower limb ischemia. a safety studyM Haumer, M Atteneder, R Ahmadi, et al.
VASA. Zeitschrift Fur Gefasskrankheiten|January 1, 1983
[A 7-years clinical course of a 41-year-old female patient with Takayasu disease]E Minar, H Ehringer, L Marosi, et al.
Thrombosis Research|November 1, 1988
Lack of influence of low-dose acetylsalicylic acid (100 mg daily) on platelet survival time, beta-thromboglobulin and platelet factor 4 in patients with peripheral arterial occlusive diseaseE Minar, H Ehringer, M Jung, et al.
VASA. Supplementum|January 1, 1990
[Hemorheologic findings in patients with heart valve replacement]R Koppensteiner, A Moritz, W Schlick, et al.
Pageof 20

Showing results (51-60 of 194) with videos related to

Sort By:
Pageof 20
VASA. Zeitschrift Fur Gefasskrankheiten|January 1, 1984
[Thrombolysis using urokinase in acute phlebothrombosis]E Minar, H Ehringer, L Marosi, et al.
Thrombosis and Haemostasis|October 22, 1990
D-dimer in local thrombolytic therapy with low doses of recombinant human tissue-type plasminogen activator (rt-PA) in patients with peripheral arterial occlusive diseaseR Koppensteiner, W Speiser, E Minar, et al.
VASA. Supplementum|January 1, 1990
[Percutaneous transluminal angioplasty of subclavian stenoses]A Ahmadi, E Minar, R Koppensteiner, et al.
Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association|January 1, 1983
Pyridoxine therapy in patients with renal calcium oxalate calculiP Balcke, P Schmidt, J Zazgornik, et al.
Zeitschrift Fur Kardiologie|November 1, 1986
[Complete AV block in a heart catheter study using a Swan-Ganz catheter]G Mostbeck, A Gassner, G Sommer, et al.
Annals of Hematology|October 11, 2003
Influence of systemic inflammation on efficiency of antiplatelet therapy in PAOD patientsS Ziegler, E Alt, M Brunner, et al.
Thrombosis Research|September 25, 2001
Coadministration of low-dose urokinase and abciximab in thrombolysis for lower limb ischemia. a safety studyM Haumer, M Atteneder, R Ahmadi, et al.
VASA. Zeitschrift Fur Gefasskrankheiten|January 1, 1983
[A 7-years clinical course of a 41-year-old female patient with Takayasu disease]E Minar, H Ehringer, L Marosi, et al.
Thrombosis Research|November 1, 1988
Lack of influence of low-dose acetylsalicylic acid (100 mg daily) on platelet survival time, beta-thromboglobulin and platelet factor 4 in patients with peripheral arterial occlusive diseaseE Minar, H Ehringer, M Jung, et al.
VASA. Supplementum|January 1, 1990
[Hemorheologic findings in patients with heart valve replacement]R Koppensteiner, A Moritz, W Schlick, et al.
Pageof 20